These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
351 related articles for article (PubMed ID: 17628166)
21. Effect of linker variation on the stability, potency, and efficacy of carcinoma-reactive BR64-doxorubicin immunoconjugates. Trail PA; Willner D; Knipe J; Henderson AJ; Lasch SJ; Zoeckler ME; TrailSmith MD; Doyle TW; King HD; Casazza AM; Braslawsky GR; Brown J; Hofstead SJ; Greenfield RS; Firestone RA; Mosure K; Kadow KF; Yang MB; Hellström KE; Hellström I Cancer Res; 1997 Jan; 57(1):100-5. PubMed ID: 8988048 [TBL] [Abstract][Full Text] [Related]
22. Plasmid pORF-hTRAIL and doxorubicin co-delivery targeting to tumor using peptide-conjugated polyamidoamine dendrimer. Han L; Huang R; Li J; Liu S; Huang S; Jiang C Biomaterials; 2011 Feb; 32(4):1242-52. PubMed ID: 20971503 [TBL] [Abstract][Full Text] [Related]
23. Formulation and cytotoxicity of doxorubicin nanoparticles carried by dry powder aerosol particles. Azarmi S; Tao X; Chen H; Wang Z; Finlay WH; Löbenberg R; Roa WH Int J Pharm; 2006 Aug; 319(1-2):155-61. PubMed ID: 16713150 [TBL] [Abstract][Full Text] [Related]
24. Construction and evaluation of PAMAM-DOX conjugates with superior tumor recognition and intracellular acid-triggered drug release properties. Cheng L; Hu Q; Cheng L; Hu W; Xu M; Zhu Y; Zhang L; Chen D Colloids Surf B Biointerfaces; 2015 Dec; 136():37-45. PubMed ID: 26360738 [TBL] [Abstract][Full Text] [Related]
25. Targeted and pH-responsive delivery of doxorubicin to cancer cells using multifunctional dendrimer-modified multi-walled carbon nanotubes. Wen S; Liu H; Cai H; Shen M; Shi X Adv Healthc Mater; 2013 Sep; 2(9):1267-76. PubMed ID: 23447549 [TBL] [Abstract][Full Text] [Related]
26. Novel method of doxorubicin-SPION reversible association for magnetic drug targeting. Munnier E; Cohen-Jonathan S; Linassier C; Douziech-Eyrolles L; Marchais H; Soucé M; Hervé K; Dubois P; Chourpa I Int J Pharm; 2008 Nov; 363(1-2):170-6. PubMed ID: 18687392 [TBL] [Abstract][Full Text] [Related]
27. Poly(amidoamine) Dendrimer-Doxorubicin Conjugates: In Vitro Characteristics and Pseudosolution Formulation in Pressurized Metered-Dose Inhalers. Zhong Q; da Rocha SR Mol Pharm; 2016 Mar; 13(3):1058-72. PubMed ID: 26832992 [TBL] [Abstract][Full Text] [Related]
28. Partly PEGylated polyamidoamine dendrimer for tumor-selective targeting of doxorubicin: the effects of PEGylation degree and drug conjugation style. Zhu S; Hong M; Tang G; Qian L; Lin J; Jiang Y; Pei Y Biomaterials; 2010 Feb; 31(6):1360-71. PubMed ID: 19883938 [TBL] [Abstract][Full Text] [Related]
29. Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer. Wong HL; Bendayan R; Rauth AM; Wu XY J Control Release; 2006 Dec; 116(3):275-84. PubMed ID: 17097178 [TBL] [Abstract][Full Text] [Related]
30. Conjugates of doxorubicin with graft HPMA copolymers for passive tumor targeting. Etrych T; Chytil P; Mrkvan T; Sírová M; Ríhová B; Ulbrich K J Control Release; 2008 Dec; 132(3):184-92. PubMed ID: 18534705 [TBL] [Abstract][Full Text] [Related]
31. Prostate cancer cell death produced by the co-delivery of Bcl-xL shRNA and doxorubicin using an aptamer-conjugated polyplex. Kim E; Jung Y; Choi H; Yang J; Suh JS; Huh YM; Kim K; Haam S Biomaterials; 2010 Jun; 31(16):4592-9. PubMed ID: 20206379 [TBL] [Abstract][Full Text] [Related]
32. Targeted delivery of doxorubicin: drug delivery system based on PAMAM dendrimers. Yabbarov NG; Posypanova GA; Vorontsov EA; Popova ON; Severin ES Biochemistry (Mosc); 2013 Aug; 78(8):884-94. PubMed ID: 24228876 [TBL] [Abstract][Full Text] [Related]
33. Folate-decorated maleilated pullulan-doxorubicin conjugate for active tumor-targeted drug delivery. Zhang H; Li F; Yi J; Gu C; Fan L; Qiao Y; Tao Y; Cheng C; Wu H Eur J Pharm Sci; 2011 Apr; 42(5):517-26. PubMed ID: 21352909 [TBL] [Abstract][Full Text] [Related]
34. Synthesis and characterization of a multifunctional gold-doxorubicin nanoparticle system for pH triggered intracellular anticancer drug release. Khutale GV; Casey A Eur J Pharm Biopharm; 2017 Oct; 119():372-380. PubMed ID: 28736333 [TBL] [Abstract][Full Text] [Related]
35. Characterisation and tumour targeting of PEGylated polylysine dendrimers bearing doxorubicin via a pH labile linker. Kaminskas LM; Kelly BD; McLeod VM; Sberna G; Owen DJ; Boyd BJ; Porter CJ J Control Release; 2011 Jun; 152(2):241-8. PubMed ID: 21315119 [TBL] [Abstract][Full Text] [Related]
36. Biodistribution of doxorubicin-alkylated poly(L-lysine citramide imide) conjugates in an experimental model of peritoneal carcinomatosis after intraperitoneal administration. Colombo PE; Boustta M; Poujol S; Pinguet F; Rouanet P; Bressolle F; Vert M Eur J Pharm Sci; 2007 May; 31(1):43-52. PubMed ID: 17383164 [TBL] [Abstract][Full Text] [Related]
37. Peptide dendrimer-Doxorubicin conjugate-based nanoparticles as an enzyme-responsive drug delivery system for cancer therapy. Zhang C; Pan D; Luo K; She W; Guo C; Yang Y; Gu Z Adv Healthc Mater; 2014 Aug; 3(8):1299-308. PubMed ID: 24706635 [TBL] [Abstract][Full Text] [Related]
38. [The Combined Effects of Ionizing Radiation and Dendritic Polymers Loaded with Doxorubicin on the MCF-7 Breast Cancer Cell Line]. Zamulaeva IA; Pronyushkina KA; Matchuk ON; Yabbarov NG; Nikolskaya ED; Kondrasheva IG Radiats Biol Radioecol; 2015; 55(6):591-7. PubMed ID: 26964344 [TBL] [Abstract][Full Text] [Related]
39. Self-assembled oligopeptide nanostructures for co-delivery of drug and gene with synergistic therapeutic effect. Wiradharma N; Tong YW; Yang YY Biomaterials; 2009 Jun; 30(17):3100-9. PubMed ID: 19342093 [TBL] [Abstract][Full Text] [Related]
40. RGD peptide-modified multifunctional dendrimer platform for drug encapsulation and targeted inhibition of cancer cells. He X; Alves CS; Oliveira N; Rodrigues J; Zhu J; Bányai I; Tomás H; Shi X Colloids Surf B Biointerfaces; 2015 Jan; 125():82-9. PubMed ID: 25437067 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]